Lake Street lowered the firm’s price target on Checkpoint Therapeutics to $32 from $41 and keeps a Buy rating on the shares after the company announced FDA has accepted for filing the cosibelimab BLA ahead of schedule, set a PDUFA date of January 3, 2024, and does not plan to hold an Advisory Committee meeting. The firm, which believes this de-risks cosibelimab’s regulatory pathway, noted that its lower price target reflects the impact of the company’s recent financing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics announces FDA filing acceptance of BLA for cosibelimab
- Checkpoint sells 1.43M shares at $5.25 in registered direct offering
- Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
- Checkpoint Therapeutics price target adjusted to $41 at Lake Street after split